Published in Front Oncol on January 11, 2016
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA (2010) 10.97
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 5.03
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys (1999) 4.27
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys (2002) 4.01
Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol (2008) 3.72
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol (2013) 3.70
Particle radiation therapy using proton and heavier ion beams. J Clin Oncol (2007) 3.13
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol (2011) 3.12
Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol (1995) 3.08
Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys (1995) 3.05
Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys (2005) 3.05
Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys (2001) 2.94
Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 2.80
Charged particles in radiation oncology. Nat Rev Clin Oncol (2009) 2.78
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 2.66
Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest (2003) 2.60
Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys (2005) 2.58
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
The stereotaxic method and radiosurgery of the brain. Acta Chir Scand (1951) 2.43
Prescribing, recording, and reporting proton-beam therapy: contents. J ICRU (2007) 2.42
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys (2007) 2.42
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Radiological use of fast protons. Radiology (1946) 2.27
Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 2.26
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol (2009) 2.21
Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 2.15
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 2.15
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2009) 2.06
Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol (2007) 2.03
The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol) (2003) 1.96
American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2004) 1.94
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.80
Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 1.77
The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J Clin Oncol (2013) 1.73
Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol (2015) 1.72
Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol (2010) 1.65
Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Radiat Oncol Biol Phys (1995) 1.63
Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys (2007) 1.56
What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys (1999) 1.55
Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol (2010) 1.55
Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys (2006) 1.50
Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.44
The Titanic and the Iceberg: prostate proton therapy and health care economics. J Clin Oncol (2007) 1.41
Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys (2004) 1.41
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.39
Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer (1998) 1.37
Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose. Phys Med Biol (2000) 1.31
Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys (2005) 1.29
The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer (2011) 1.29
High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.28
Curative treatment of Stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys (2007) 1.27
Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol (2003) 1.27
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2014) 1.26
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res (2005) 1.24
Quantification of the relative biological effectiveness for ion beam radiotherapy: direct experimental comparison of proton and carbon ion beams and a novel approach for treatment planning. Int J Radiat Oncol Biol Phys (2010) 1.19
A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med (2010) 1.19
Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract (2012) 1.18
The incorporation of the concept of minimum RBE (RbEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol (2007) 1.17
Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys (2007) 1.15
Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys (2004) 1.14
Carbon-ion radiation therapy for prostate cancer. Int J Urol (2012) 1.13
Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer (2011) 1.13
Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol (2011) 1.13
Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol (2010) 1.08
Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys (2008) 1.08
The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev (2010) 1.08
Extracranial stereotactic radioablation: physical principles. Acta Oncol (2003) 1.07
Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol (2014) 1.07
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context. Radiat Oncol (2014) 1.03
High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys (2013) 1.02
Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. Cancer (2013) 1.02
Stereotactic ablative radiotherapy: what's in a name? Pract Radiat Oncol (2011) 1.01
Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer. Cancer Sci (2010) 0.99
Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol (2008) 0.97
Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol (2008) 0.95
Treatment planning for a scanned carbon beam with a modified microdosimetric kinetic model. Phys Med Biol (2010) 0.93
Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer (2011) 0.93
Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys (2012) 0.93
Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res (2005) 0.92
Assessment of potential advantages of relevant ions for particle therapy: a model based study. Med Phys (2015) 0.90
Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol (2012) 0.89
Predicting realistic RBE values for clinically relevant radiotherapy schedules. Int J Radiat Biol (1997) 0.89
Radiological physics characteristics of the extracted heavy ion beams of the bevatron. Science (1971) 0.89
Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol (2014) 0.88
Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. Phys Med Biol (2010) 0.87
Cost-effectiveness analysis comparing conventional versus stereotactic body radiotherapy for surgically ineligible stage I non-small-cell lung cancer. J Oncol Pract (2014) 0.86
Optimization of radiation therapy: integral-response of a model biological system. Int J Radiat Oncol Biol Phys (1982) 0.84
Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys (1988) 0.84
Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. BMC Cancer (2014) 0.83
Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys (1999) 0.82